Zymeworks Inc.

Equities

ZYME

US98985Y1082

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-15 pm EDT 5-day change 1st Jan Change
10.27 USD +1.99% Intraday chart for Zymeworks Inc. +14.88% -1.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy MT
Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers DJ
Zymeworks Inc. Announces FDA Clearance of Investigational New Drug Application for ZW171 CI
Transcript : Zymeworks Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:58 PM
Zymeworks Inc. Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer CI
Sector Update: Health Care Stocks Decline Premarket Monday MT
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy MT
Transcript : Zymeworks Inc., Q1 2024 Earnings Call, May 02, 2024
Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting CI
Zymeworks Inc. Removes Christopher Astle from the Positions of Chief Financial Officer CI
Zymeworks Inc. Removes Dr. Christopher Astle from the Positions of Senior Vice President CI
Zymeworks Inc. Announces the Composition of the Committees CI
Zymeworks Inc. Announces Appointment of Neil Gallagher to Its Board of Directors and as Member of the Research and Development Committee, Effective April 2, 2024 CI
Wells Fargo Adjusts Price Target on Zymeworks to $14 From $12, Maintains Overweight Rating MT
H.C. Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Rating MT
Zymeworks Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Zymeworks Inc., Q4 2023 Earnings Call, Mar 06, 2024
Zymeworks Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Zymeworks Inc. to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting CI
Zymeworks Inc. Appoints Scott Platshon as Director CI
Transcript : Zymeworks Inc. Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-22-2024 08:00 AM
Zymeworks Announces Appointment of Dr. Alessandra Cesano to Its Board of Directors CI
Transcript : Zymeworks Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 08:15 AM
Zymeworks Insider Sold Shares Worth $257,845, According to a Recent SEC Filing MT
Chart Zymeworks Inc.
More charts
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
10.27 USD
Average target price
14.08 USD
Spread / Average Target
+37.08%
Consensus
  1. Stock Market
  2. Equities
  3. ZYME Stock
  4. News Zymeworks Inc.
  5. Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy